WATCH LIVE
timothy sykes logo
MRNA Stock Jumps As Flu Win And Pipeline Reset Ignite Momentum Thumbnail
G Google News

MRNA Stock Jumps As Flu Win And Pipeline Reset Ignite Momentum

TIM SYKES•UPDATED JUN. 26, 2026, 11:33 AM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Moderna Inc. stocks have been trading up by 14.04 percent after promising new mRNA vaccine trial results boosted investor optimism.

Key Takeaways

  • FDA advisers unanimously backed Moderna’s mRNA‑1010/mFLUSIVA flu shot for adults 50–64 and 65+, de‑risking a key diversification asset and sparking roughly a 4% intraday move in MRNA.
  • Jefferies kept a Hold rating and $45 target on Moderna, reminding traders that substantial flu revenue is not expected until around 2027 despite the strong advisory vote.
  • A sweeping restructuring toward three commercial franchises and multiple 2027–2028 launches pushed MRNA up about 6.3%, signaling support for the post‑COVID pivot.
  • At its 2026/06/25 Science Day, Moderna highlighted a broader mRNA platform in oncology, autoimmune disease, and rare disorders, plus AI‑ and robotics‑driven R&D and late‑stage assets like intismeran.
  • Plans to invest in German production sites and potential BioNTech plant acquisitions sent MRNA more than 8% higher, underscoring an aggressive push on global manufacturing capacity.

Candlestick Chart

Live Update At 11:33:01 EDT: On Friday, June 26, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 14.04%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MRNA is trading like a momentum name again. Over the last few weeks, Moderna stock has ripped from about $46 on 2026/06/01 to $68.04 on 2026/06/26. That is roughly a 48% move off the lows. For short‑term traders, that kind of extension matters as much as any lab result.

Look at the recent daily action. MRNA based in the high $40s and low $50s, then accelerated after mid‑June catalysts. On 2026/06/17 the stock closed at $61.80 after opening at $56.21, lining up with headlines about a new operating model and German expansion. By 2026/06/26, the intraday range stretched from $59.23 to $69.29, a wide, volatile candle with strong buying pressure into the close.

Intraday, the 5‑minute chart shows a clean trend day. After the opening push from roughly $61 to mid‑$60s, MRNA held higher lows and marched into the high $60s by late morning, a classic grind‑up pattern. For active trading, that tells you dip buyers are in control.

More Breaking News

Fundamentally, though, Moderna is still burning cash. Latest quarterly revenue is about $389M, with a net loss near $1.34B and free cash flow around –$692M. Gross margin sits near 22.6%, but EBIT margins are deeply negative, reflecting heavy R&D and launch prep. The balance sheet is solid, with about $5.21B in cash and short‑term investments and low debt (total debt‑to‑equity roughly 0.17). For traders, that mix means MRNA trades on news, pipeline, and sentiment far more than on current earnings.

Why Traders Are Watching MRNA Right Now

Moderna just landed the kind of news momentum traders love. An FDA advisory committee voted 9‑0 that its mRNA‑1010/mFLUSIVA flu vaccine has a favorable benefit–risk profile in adults 50–64 and 65+. Historically, a unanimous panel is a strong tell for eventual approval ahead of the 2026/08/05 PDUFA date. For MRNA, that is the first real path to a seasonal revenue stream not powered by COVID.

The market reaction was clear. FDA advisers backed full approval for adults 50–64 and accelerated approval for those 65+, lifting Moderna stock roughly 4% intraday. Another outlet noted the unanimous recommendation for adults 50+, framing it as a major step toward commercialization. Traders read that as de‑risking of a big pipeline asset.

Wall Street is not going full moonshot, though. Jefferies kept a Hold rating and a $45 target, even after the vote. Their message: confidence in eventual flu approval is higher, but meaningful flu cash will not really show up until around 2027. For MRNA traders, that split view is key. The story is less about next quarter’s EPS and more about a 2027–2028 revenue arc.

At the same time, Moderna is reshaping the whole business. The company is restructuring around three commercial franchises and preparing for multiple vaccine, oncology, and rare‑disease launches over 2027–2028. When Moderna announced this new operating model, MRNA jumped about 6.3%, making it one of the top S&P 500 movers that day. That is the tape telling you the Street is buying the diversification story.

Then comes capacity. Moderna plans to invest in German production sites and is eyeing plants BioNTech plans to close. Headlines around those moves pushed MRNA 8–12% higher across several reports, even as the broader market sold off on rate fears. Traders who watch relative strength will notice: MRNA is starting to trade like a leader again.

Layer on the 2026/06/25 Science Day, where Moderna highlighted four approved products, a growing infectious disease franchise, late‑stage projects like intismeran and a propionic acidemia program, plus an AI‑ and robotics‑driven R&D engine. MRNA also showcased oncology work, including a T‑cell engager in multiple myeloma, an ovarian cancer follow‑on program, and an in vivo CAR‑T candidate. None of this pays the bills yet, but it builds the “platform” narrative that momentum traders love to surf when the chart confirms.

Conclusion

For active traders, Moderna is shifting from a COVID‑only legacy into a high‑beta platform story. The unanimous VRBPAC support for mFLUSIVA gives MRNA a clear regulatory roadmap into 2026 and reduces one of the biggest binary risks on the table. At the same time, the restructuring into three franchises, the German manufacturing push, and the expanding oncology and rare‑disease pipeline all point toward a very different company profile by 2027–2028.

The financials still show heavy losses and negative free cash flow, so Moderna remains a story stock. That is exactly why the chart and news flow matter so much. Right now, they are aligned: strong uptrend on the daily chart, clean intraday momentum, and a drumbeat of positive headlines around flu, capacity, and Science Day.

Traders should remember what Tim Sykes pounds into his students: “The market doesn’t care about your opinion, only the price action and the catalyst.” As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. With MRNA, the catalysts are lining up and the price action is confirming, but the only thing that counts in trading is how you manage risk. This article is for educational and research purposes only, so use it as a starting point, do your own homework, and always have a plan before you trade MRNA or any other volatile biotech.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”